05/26/2026
The Medicare GLP-1 Bridge
The conversation around GLP-1 medications has been impossible to ignore. Drugs like Wegovy and Zepbound have transformed obesity treatment, but access has remained limited for Medicare beneficiaries.
That’s starting to change. With the large numbers of beneficiaries needing to lose weight for their health, certain GLP-1 medications are now coverable by Medicare Part D.
However, there are many factors that are concerning in this new development. Firstly, the cost of medication is still very expensive, which will cause financial strain on Part D and MAPD carriers. With so many turning to GLP-1 drugs for weight loss, there is a surge in demand that could lead to shortages. This creates a large concern regarding the access and affordability for beneficiaries, as well as plan risk exposure.
Luckily, the Centers of Medicare & Medicaid Services (CMS) is stepping in with a temporary solution, called the GLP-1 Bridge, to see if they can make this medication more accessible without breaking the system financially.
What Will the GLP-1 Bridge Do?
The GLP-1 Bridge will run from July 1, 2026, until December 31, 2027. It will do the following things:
Shield Part D and MAPD carriers by having CMS handle all GLP-1 approvals, claims, and payments.
Reduce the cost of GLP-1 medications for eligible Medicare beneficiaries, ensuring greater access.
Allow CMS to test this new program without impacting carriers or beneficiaries.
What Will Clients Pay for Their GLP-1 Medication?
Clients will pay a flat $50 copay for GLP-1 medications once approved. Since the GLP-1 Bridge is run through CMS and not through Part D, the $50 does not count towards the Part D out-of-pocket limits or deductibles. Low Income Subsidy (Extra Help) also does not apply to these claims.
Which GLP-1 Medications are Covered?
Currently, the GLP-1 Bridge focuses on:
Wegovy
Zepbound
Foundayo
These drugs have been approved specifically for weight loss, not only for diabetics, like Ozempic.
Who Qualifies?
Eligibility isn’t automatic. To qualify, clients must meet specific Body Mass Index (BMI) and health condition criteria. In addition, their provider must prescribe the medication and submit prior authorization through CMS.
Typical eligible BMI includes:
BMI equal to or greater than 35.
OR
BMI equal or greater than 30, with conditions like hypertension, heart failure, or kidney disease.
OR
BMI equal or greater than 27, with risk factors like pre-diabetes or prior cardiovascular events.
The beneficiary must also be enrolled in a standalone prescription drug plan (PDP) or Medicare Advantage (MA) coordinated care plan (i.e., HMO, HMOPOS, or Local or Regional PPO plans) that offers prescription drug coverage (MAPD plans) in CY 2026.
The Bigger Picture
The GLP-1 Bridge signals a few important industry shifts:
1. Medicare is Testing New Cost Models
Instead of pushing costs to carriers, CMS is stepping in directly.
2. Demand is Driving Policy
GLP-1 usage has exploded, and CMS is being forced to adapt.
People are now trying to access injectable peptides for weight loss, driven by influencers and wellness centers. However, these have not been tested or reviewed by the Food & Drug Administration (FDA).
3. Long-Term Coverage is Still Unclear
This program is a bridge to a future model called the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE). Under BALANCE, CMS would negotiate lower prices directly with eligible GLP-1 manufacturers on behalf of the state Medicaid agencies and Part D plans. However, there are no guaranteed long-term solutions yet and clients who access GLP-1 medication under this bridge could face a gap or a required plan switch during AEP.
“This is a CMS program, not a plan benefit.”
“Your Part D plan doesn’t impact eligibility.”
“Your doctor determines whether you qualify.”
“This is temporary and currently scheduled to end in 2027.”
